- Home
- BTCT vs BOLD Comparison
BTCT vs BOLD Comparison
Compare BTCT & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTCT | BOLD |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 26.2M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | BTCT | BOLD |
|---|---|---|
| Price | $1.74 | $1.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 96.7K | ★ 185.6K |
| Earning Date | 11-14-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,427,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 83.61 | N/A |
| 52 Week Low | $1.57 | $1.00 |
| 52 Week High | $9.90 | $3.45 |
Technical Indicators
Market Signals| Indicator | BTCT | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 41.42 | 49.33 |
| Support Level | $1.82 | $1.11 |
| Resistance Level | $2.05 | $1.20 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 25.71 | 85.00 |
Price Performance
Historical ComparisonAbout BTCT BTC Digital Ltd.
BTC Digital Ltd is a crypto asset technology company based in the U.S. with a focus on bitcoin mining. The company also generates revenue through mining machine resale and rental business operations. Geographically, the financial assets of the company is located in the United States, Singapore, Hong Kong and the PRC.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.